Updates are available Correction dated 2025-04-05

Article History

Received: 22 August 2024

Accepted: 10 December 2024

First Online: 10 February 2025

Change Date: 5 April 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-025-01372-8

Conflict of Interest

: Kenneth B Gordon reports grant support and consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, and UCB, and has received consulting fees from Amgen, Almirall, Dermira, LEO Pharma, Pfizer, and Sun Pharmaceutical Industries. Yayoi Tada declares receiving honoraria and/or grants from AbbVie, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB. Milan J Anadkat declares paid activities as a current advisor or consultant for Biolinq, Boehringer Ingelheim, Eli Lilly, Novocure, Protagonist Therapeutics, Kintara, Evommune, and SpringWorks Therapeutics; has served as a prior consultant or advisor for AbbVie, Adgero Pharmaceuticals, Amgen, Aspire Bariatrics, AstraZeneca, Biogen, Bristol Myers Squibb, ImClone Systems, Innovaderm Research, OnQuality Pharmaceuticals, Therakos, Veloce BioPharma, and UCB; and has served as an investigator for AbbVie, AnaptysBio, Biogen, Boehringer Ingelheim, ChemoCentryx, Eli Lilly, InCyte, InflaRx, Hana Biosciences, Hoth, Lutris, MoonLake, Novartis, OnQuality Pharmaceuticals, Regeneron, Sanofi, UCB, Veloce BioPharma, XBiotech, and Xoma. Siew Eng Choon declares paid activities as an advisor, speaker, or consultant for AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sanofi, and UCB. Boni Elewski has received research grants (paid to institution) from AbbVie, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatology, Pfizer, and UCB; and is a consultant for Amgen (previously Celgene), Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Ortho Dermatology, and UCB. Jonathan N Barker has received honoraria and/or research grants from AbbVie, Almirall, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Samsung, and Sun Pharmaceutical Industries. Kilian Eyerich declares having attended advisory boards and/or received speaker fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Arash Mostaghimi has received consulting fees from Abbvie, ACOM Health, Bioniz, Boehringer Ingelheim, Concert, Digital Diagnostics, Eli Lilly, Equillium, Hims & Hers Health, and Pfizer; equity from ACOM Health, Figure 1, and Hims & Hers Health; licensing/royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte. Ming Tang, Thomas Haeufel, and Christian Thoma are employees of Boehringer Ingelheim. Diamant Thaçi has served as a consultant, advisory board member, and/or investigator for AbbVie, Almirall, Amgen, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Janssen-Cilag, LEO Pharma, L’Oreal, New Bridge, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, and UCB.

: The trials were conducted in accordance with the trial protocol, the International Council for Harmonisation Good Clinical Practice guidelines, Regulation No. 536/2014 (EU [European Union]), the Japanese Good Clinical Practice regulations, and applicable local regulations. The studies were approved by ethics committees of participating institutions and countries. The authors acknowledge that the original studies obtained the necessary patient consent.